CYP17A1 Inhibitors Market to Reach USD 1.35 Billion by 2025, Fueled by Advancements in Prostate Cancer Therapeutics The CYP17A1 inhibitors market is projected to attain USD 1,350 million by 2025, ...

The CYP17A1 inhibitors market is projected to attain USD 1,350 million by 2025, expanding at a robust CAGR of 8.5% between 2025 and 2032, supported by strong pipeline activity, ...

Steroidogenesis-mediated production of neurosteroids is important for brain homeostasis. Cytochrome P450 17A1 (CYP17A1), which converts pregnenolone to dehydroepiandrosterone (DHEA) in endocrine ...

VT-464 is a novel, non-steroidal, small molecule CYP17A1 inhibitor with selectivity for the lyase activity of this dual enzyme. The objective of this study was to evaluate the anti-cancer activity of ...

Background: Abiraterone acetate (AA) is a potent inhibitor of enzymes encoded by CYP17A1 and HSD3β2 in the sex steroid synthesis pathway in the testis, adrenal glands, and prostate cancer cells. While ...